Drug Trial Radar · NCT00419341
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
Last checked: Nov 19, 2026Latest source record: Jan 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Nov 2006
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
Conditions
- Primary Immune Deficiency
Interventions
Human Normal Immunoglobulin for Subcutaneous AdministrationBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Clinically Documented Serious Bacterial Infections (SBIs) (MITT Population)Time frame: Efficacy period: up to 12 months (week 13 to the completion visit)
- Area Under the Concentration-time Curve (AUC) of Total Serum Immunoglobulin G (IgG)Time frame: Measured during a single dosing interval after at least 12 weeks of stable subcutaneous (SC) dosing with IgPro20 treatment
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Study Site
Los Angeles, California
Study Site
Los Angeles, California
Study Site
Centennial, Colorado
Study Site
North Palm Beach, Florida
Study Site
Atlanta, Georgia
Study Site
Fort Wayne, Indiana
Study Site
Indianapolis, Indiana
Study Site
Iowa City, Iowa
Study Site
St Louis, Missouri
Study Site
Newark, New Jersey
Study Site
New York, New York
Study Site
Philadelphia, Pennsylvania
Study Site
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.